ROCK and Nuclear Factor-κB–dependent Activation of Cyclooxygenase-2 by Rho GTPases: Effects on Tumor Growth and Therapeutic Consequences
Open Access
- 1 July 2003
- journal article
- Published by American Society for Cell Biology (ASCB) in Molecular Biology of the Cell
- Vol. 14 (7) , 3041-3054
- https://doi.org/10.1091/mbc.e03-01-0016
Abstract
Rho GTPases are overexpressed in a variety of human tumors contributing to both tumor proliferation and metastasis. Recently, several studies demonstrate an essential role of transcriptional regulation in Rho GTPases-induced oncogenesis. Herein, we demonstrate that RhoA, Rac1, and Cdc42 promote the expression of cyclooxygenase-2 (COX-2) at the transcriptional level by a mechanism that is dependent on the transcription factor nuclear factor-κB (NF-κB), but not Stat3, a transcription factor required for RhoA-induced tumorigenesis. With respect to RhoA, this effect is dependent on ROCK, but not PKN. Treatment of RhoA-, Rac1-, and Cdc42-transformed epithelial cells with Sulindac and NS-398, two well-characterized nonsteroid antiinflammatory drugs (NSAIDs), results in growth inhibition as determined by cell proliferation assays. Accordingly, tumor growth of RhoA-expressing epithelial cells in syngeneic mice is strongly inhibited by NS-398 treatment. The effect of NSAIDs over RhoA-induced tumor growth is not exclusively dependent on COX-2 because DNA-binding of NF-κB is also abolished upon NSAIDs treatment, resulting in complete loss of COX-2 expression. Finally, treatment of RhoA-transformed cells with Bay11-7083, a specific NF-κB inhibitor, leads to inhibition of cell proliferation. We suggest that treatment of human tumors that overexpress Rho GTPases with NSAIDs and drugs that target NF-κB could constitute a valid antitumoral strategy.Keywords
This publication has 52 references indexed in Scilit:
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- Role of Rac and Cdc42 in lysophosphatidic acid-mediated cyclo-oxygenase-2 gene expressionBiochemical Journal, 2002
- RHO–GTPases and cancerNature Reviews Cancer, 2002
- Differential Requirement for Rho Family GTPases in an Oncogenic Insulin-like Growth Factor-I Receptor-induced Cell TransformationPublished by Elsevier ,2001
- Nuclear Factor-κB Regulates Cyclooxygenase-2 Expression and Cell Proliferation in Human Gastric Cancer CellsLaboratory Investigation, 2001
- Activation of Rho Is Required for Ligand-independent Oncogenic Signaling by a Mutant Epidermal Growth Factor ReceptorJournal of Biological Chemistry, 2001
- Differential Regulation of COX-2 Transcription by Ras- and Rho-Family of GTPasesBiochemical and Biophysical Research Communications, 2000
- Regulation of Urokinase Receptor Transcription by Ras- and Rho-Family GTPasesBiochemical and Biophysical Research Communications, 2000
- The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformationOncogene, 1999
- Rho proteins induce metastatic properties in vivoOncogene, 1997